Search results for "asta"

showing 10 items of 3213 documents

Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer.

2013

To characterize the stage-specific prognostic relevance of preoperative systemic inflammatory response, defined by C-reactive protein (CRP), in colon cancer (CC) patients.Data from CC patients operated on from 1998 to 2007 at three hospitals from three different Nordic countries were collected retrospectively from national registries, local databases and/or patient records. Patients with emergency surgery, infection or auto-immune disease were excluded. Associations between clinical or histopathological variables and CRP were assessed. Patients were followed from the date of surgery to death or end of follow-up. Disease-specific survival (DSS) was the main endpoint.In total, 525 patients wi…

AdultMalemedicine.medical_specialtyColorectal cancerIncreased C-reactive proteinDiseaseGastroenterologyInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingStage (cooking)Stage specificSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overbusiness.industryElevated crpRetrospective cohort studyHematologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgerySurvival RateC-Reactive ProteinOncologyLymphatic MetastasisColonic NeoplasmsFemaleNeoplasm GradingbusinessFollow-Up StudiesActa oncologica (Stockholm, Sweden)
researchProduct

Cryotherapy for liver metastases

2000

Cryotherapy is undergoing a renaissance in the treatment of nonresectable liver tumors. In a prospective case control study we assessed the morbidity, mortality, and efficacy of hepatic cryotherapy for liver metastases. Between January 1996 and September 1999 a total of 54 cryosurgical procedures were performed on 49 patients (median age 66 years, 21 women) with liver metastases. Patient, tumor, and operative details were recorded prospectively. Liver metastases originated from colorectal cancer (n=37), gastric cancer (n=3), renal cell carcinoma (n=2), and other primaries (n=7). Median follow-up was 13 months (1-32). The median number of liver metastases was 3 (range 1-10) with a median dia…

AdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCryotherapyCryosurgeryMetastasisStomach NeoplasmsRenal cell carcinomaInternal medicinemedicineHumansProspective StudiesAgedTumor markerbusiness.industryLiver NeoplasmsGastroenterologyCancerCryoablationMiddle AgedHepatologymedicine.diseaseSurgeryTreatment OutcomeCase-Control StudiesFemaleMorbidityNeoplasm Recurrence LocalColorectal NeoplasmsbusinessInternational Journal of Colorectal Disease
researchProduct

Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery

2005

Background: Population based colorectal cancer survival among patients diagnosed in 1985–89 was lower in Europe than in the USA (45% v 59% five year relative survival). Aims: To explain this difference in survival using a new analytic approach for patients diagnosed between 1990 and 1991. Subjects: A total of 2492 European and 11 191 US colorectal adenocarcinoma patients registered by 10 European and nine US cancer registries. Methods: We obtained clinical information on disease stage, number of lymph nodes examined, and surgical treatment. We analysed three year relative survival, calculating relative excess risks of death (RERs, referent category US patients) adjusted for age, sex, site, …

AdultMalemedicine.medical_specialtyColorectal cancerpopulation based cancer registriescolorectal cancerAdenocarcinomasurvivalsurgerylymph nodesmedicineHumansRegistriesStage (cooking)Risk factorUSASurvival analysisAgedNeoplasm StagingColorectal CancerRelative survivalcolorectal cancer; population based cancer registries; surgery; lymph nodes; survival; USA; Europebusiness.industryGastroenterologyAbsolute risk reductionCancerMiddle Agedmedicine.diseaseSurvival AnalysisUnited StatesConfidence intervalSurgeryEuropeLymphatic MetastasisFemaleColorectal NeoplasmsbusinessGut
researchProduct

Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.

2010

Objectives We aimed to assess whether concurrent administration of atorvastatin would modify the development of tolerance and endothelial dysfunction associated with sustained nitroglycerin (GTN) therapy in humans. Background Animal studies have demonstrated that administration of 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors can protect against GTN-induced endothelial dysfunction and tolerance, likely through an antioxidant mechanism. Methods Thirty-six healthy male volunteers were randomized to receive continuous transdermal GTN (0.6 mg/h) and placebo, atorvastatin (80 mg/day) alone, or continuous transdermal GTN (0.6 mg/h) with concurrent atorvastatin (80 mg/day), all for 7 …

AdultMalemedicine.medical_specialtyEndotheliumendotheliumAdolescentBrachial Arterymedicine.medical_treatmentAtorvastatinVasodilator AgentsBlood PressurePlaceboNitroglycerinYoung AdultDouble-Blind MethodHeart RateReference ValuesInternal medicinemedicineAtorvastatinHumansPyrrolesEndothelial dysfunctionSalinetolerancebiologybusiness.industryDrug Administration RoutesDrug Tolerancemedicine.diseaseVasodilationOxidative StressBlood pressuremedicine.anatomical_structureEndocrinologyHeptanoic AcidsCirculatory systemHMG-CoA reductasebiology.proteincardiovascular systemlipids (amino acids peptides and proteins)Endothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusinessmedicine.drugcirculatory and respiratory physiologyJournal of the American College of Cardiology
researchProduct

Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections

2020

Abstract Background Surgery represents the best treatment for primary gastrointestinal stromal tumors (GISTs). The aim of this study is to analyse outcomes of surgical management in order to evaluate the influence of microscopically R1 margins on survival and recurrence in patients affected by GISTs. Methods The study reviewed retrospective data from 74 patients surgically treated for primary GISTs without metastasis at diagnosis. Clinical and pathological findings, surgical procedures, information about follow up and outcomes were analyzed. Results Recurrence rate was low and no patients died in the R1 group during the follow up period. The difference in recurrence free survival for patien…

AdultMalemedicine.medical_specialtyGastrointestinal Stromal TumorsPrognosiMetastasisPositive microscopic margins03 medical and health sciences0302 clinical medicineHumansMedicineIn patientGastrointestinal stromal tumors (GISTs)Surgical treatmentPathologicalGISTsAgedRetrospective StudiesAged 80 and overGiSTbusiness.industryMargins of ExcisionGeneral MedicineMiddle AgedSurgical proceduresPrognosismedicine.diseaseSurgeryLog-rank test030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologySurgeryNeoplasm Recurrence LocalPositive microscopic marginbusinessGISTThe American Journal of Surgery
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis

2019

Abstract Background Few patients affected by gastric cancer peritoneal metastasis (GCPM) are offered locoregional treatment, despite several proof-of-efficacy trials. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has emerged in recent years as a promising tool to control peritoneal carcinomatosis. The combination of PIPAC with systemic chemotherapy may offer a greater clinical benefit than standard treatment alone. Methods A single-center cohort of 28 consecutive patients affected by GCPM was scheduled for bidirectional treatment, comprising PIPAC and systemic chemotherapy, from September 2017 to September 2019. Data recorded included safety, efficacy and survival outcomes. Ascit…

AdultMalemedicine.medical_specialtyIntraoperative Complicationmedicine.medical_treatmentPopulation03 medical and health sciences0302 clinical medicineStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicinePressureHumansProspective StudieseducationPeritoneal NeoplasmsAgedRetrospective StudiesAerosolseducation.field_of_studyChemotherapyPressurized intraperitoneal aerosol chemotherapy (PIPAC)business.industryStandard treatmentCommon Terminology Criteria for Adverse EventsMiddle AgedPrognosisSurgerySurvival RateOncologyDoxorubicin030220 oncology & carcinogenesisCohortConventional PCIPeritoneal metastasisPeritoneal Cancer Index030211 gastroenterology & hepatologySurgeryFemaleCisplatinbusinessGastric cancerFollow-Up Studies
researchProduct

Retrospective Analysis of 29 Patients with Multiple Pulmonary Metastases from Colorectal Carcinoma Resected by a 1318-nm Laser

2018

NO Abstract

AdultMalemedicine.medical_specialtyLung NeoplasmsColorectal cancerTreatment outcomeMEDLINEColorectal Neoplasm030204 cardiovascular system & hematologyFollow-Up Studie03 medical and health sciences0302 clinical medicineRetrospective StudiePositron Emission Tomography Computed TomographyRetrospective analysisMedicineHumansPneumonectomyPositron Emission Tomography-Computed TomographyRetrospective StudiesAgedNeoplasm StagingAged 80 and overbusiness.industryFollow up studiesMetastasectomyRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseLung NeoplasmTreatment OutcomeThoracotomy030220 oncology & carcinogenesisNeoplasm stagingFemaleRadiologyLaser TherapybusinessColorectal NeoplasmsFollow-Up StudiesHuman
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

"Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxa…

2010

BACKGROUND: No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine. METHODS: We investigated the independent effect of baseline clinical characteristics and physical functioning (PF) domain on RR, PFS, and OS in 310 patients who completed the EORTC QLQ-C30 questionnaire. Multivariate analyses stratified by treatment were performed. An exploratory analysis was done by grouping patients with a PF score superior or equal to the highest quartile (n = 111), included between the highest and the lowest quartiles (n = …

AdultMalemedicine.medical_specialtyMultivariate analysisColorectal cancerSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalCapecitabineTreatment Outcome; Prognosis; Aged 80 and over; Male; Retrospective Studies; Randomized Controlled Trials as Topic; Middle Aged; Kaplan-Meier Estimate; Colorectal Neoplasms; Female; Disease-Free Survival; Humans; Quality of Life; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials Phase III as Topic; Aged; Adult; Health Status Indicators; Multicenter Studies as TopicFolinic acidQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineOverall survivalHealth Status IndicatorsHumansMulticenter Studies as TopicClinical TrialsRadiology Nuclear Medicine and imagingneoplasmsmetastatic colorectal canceroxaliplatin physical functioning statusAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overbusiness.industryHematologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryOxaliplatinPhase III as TopicTreatment OutcomeClinical Trials Phase III as TopicOncologyQuartileQuality of LifeFemaleColorectal Neoplasmsbusinessmedicine.drug
researchProduct